A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases

The discovery of new drugs is required in the time of global aging and increasing populations. Traditional drug development strategies are expensive, time-consuming, and have high risks. Thus, drug repurposing, which treats new/other diseases using existing drugs, has become a very admired tactic. I...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Md. Mohaiminul Islam, Yang Wang, Pingzhao Hu
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
Q
Acceso en línea:https://doaj.org/article/3c03932404a84e9f8e1fc4635c6bc46e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:3c03932404a84e9f8e1fc4635c6bc46e
record_format dspace
spelling oai:doaj.org-article:3c03932404a84e9f8e1fc4635c6bc46e2021-11-25T18:10:24ZA Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases10.3390/life111111152075-1729https://doaj.org/article/3c03932404a84e9f8e1fc4635c6bc46e2021-10-01T00:00:00Zhttps://www.mdpi.com/2075-1729/11/11/1115https://doaj.org/toc/2075-1729The discovery of new drugs is required in the time of global aging and increasing populations. Traditional drug development strategies are expensive, time-consuming, and have high risks. Thus, drug repurposing, which treats new/other diseases using existing drugs, has become a very admired tactic. It can also be referred to as the re-investigation of the existing drugs that failed to indicate the usefulness for the new diseases. Previously published literature used maximum flow approaches to identify new drug targets for drug-resistant infectious diseases but not for drug repurposing. Therefore, we are proposing a maximum flow-based protein–protein interactions (PPIs) network analysis approach to identify new drug targets (proteins) from the targets of the FDA (Food and Drug Administration) drugs and their associated drugs for chronic diseases (such as breast cancer, inflammatory bowel disease (IBD), and chronic obstructive pulmonary disease (COPD)) treatment. Experimental results showed that we have successfully turned the drug repurposing into a maximum flow problem. Our top candidates of drug repurposing, Guanidine, Dasatinib, and Phenethyl Isothiocyanate for breast cancer, IBD, and COPD were experimentally validated by other independent research as the potential candidate drugs for these diseases, respectively. This shows the usefulness of the proposed maximum flow approach for drug repurposing.Md. Mohaiminul IslamYang WangPingzhao HuMDPI AGarticledrug–target interactionsprotein–protein interactionschronic diseasesdrug repurposingmaximum flowScienceQENLife, Vol 11, Iss 1115, p 1115 (2021)
institution DOAJ
collection DOAJ
language EN
topic drug–target interactions
protein–protein interactions
chronic diseases
drug repurposing
maximum flow
Science
Q
spellingShingle drug–target interactions
protein–protein interactions
chronic diseases
drug repurposing
maximum flow
Science
Q
Md. Mohaiminul Islam
Yang Wang
Pingzhao Hu
A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases
description The discovery of new drugs is required in the time of global aging and increasing populations. Traditional drug development strategies are expensive, time-consuming, and have high risks. Thus, drug repurposing, which treats new/other diseases using existing drugs, has become a very admired tactic. It can also be referred to as the re-investigation of the existing drugs that failed to indicate the usefulness for the new diseases. Previously published literature used maximum flow approaches to identify new drug targets for drug-resistant infectious diseases but not for drug repurposing. Therefore, we are proposing a maximum flow-based protein–protein interactions (PPIs) network analysis approach to identify new drug targets (proteins) from the targets of the FDA (Food and Drug Administration) drugs and their associated drugs for chronic diseases (such as breast cancer, inflammatory bowel disease (IBD), and chronic obstructive pulmonary disease (COPD)) treatment. Experimental results showed that we have successfully turned the drug repurposing into a maximum flow problem. Our top candidates of drug repurposing, Guanidine, Dasatinib, and Phenethyl Isothiocyanate for breast cancer, IBD, and COPD were experimentally validated by other independent research as the potential candidate drugs for these diseases, respectively. This shows the usefulness of the proposed maximum flow approach for drug repurposing.
format article
author Md. Mohaiminul Islam
Yang Wang
Pingzhao Hu
author_facet Md. Mohaiminul Islam
Yang Wang
Pingzhao Hu
author_sort Md. Mohaiminul Islam
title A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases
title_short A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases
title_full A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases
title_fullStr A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases
title_full_unstemmed A Maximum Flow-Based Approach to Prioritize Drugs for Drug Repurposing of Chronic Diseases
title_sort maximum flow-based approach to prioritize drugs for drug repurposing of chronic diseases
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/3c03932404a84e9f8e1fc4635c6bc46e
work_keys_str_mv AT mdmohaiminulislam amaximumflowbasedapproachtoprioritizedrugsfordrugrepurposingofchronicdiseases
AT yangwang amaximumflowbasedapproachtoprioritizedrugsfordrugrepurposingofchronicdiseases
AT pingzhaohu amaximumflowbasedapproachtoprioritizedrugsfordrugrepurposingofchronicdiseases
AT mdmohaiminulislam maximumflowbasedapproachtoprioritizedrugsfordrugrepurposingofchronicdiseases
AT yangwang maximumflowbasedapproachtoprioritizedrugsfordrugrepurposingofchronicdiseases
AT pingzhaohu maximumflowbasedapproachtoprioritizedrugsfordrugrepurposingofchronicdiseases
_version_ 1718411553271709696